



## OVARY MEASURE SPECIFICATIONS

### Cancer Programs Practice Profile Reports (CP<sup>3</sup>R)

#### Introduction

The Commission on Cancer's (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve the transparency with which the measures in the CP<sup>3</sup>R and RQRS reporting systems are calculated. To this end, for each measure, supporting information, three tables and a flow-diagram are provided:

- The measure type, clinical rationale and references are provided.
- The *Measure Item List* table provides each cancer registry data item used in the assessment of the indicated measure. This includes the FORDS data item name, the North American Association of Central Cancer Registry (NAACCR) item number and a brief description of each item.
- The *Case Eligibility Criteria* table itemizes the steps taken to determine whether cases belong in the measure denominator for cases diagnosed 2010 and later. Each condition is described and is accompanied by the data item and code values used in the assessment.
- The *Numerator Criteria* table illustrates how cases are assessed to determine whether they qualify for the numerator of the measure, in other words are concordant for the standard of care.
- A **flow-diagram** is provided to illustrate the steps through which cases pass as they are evaluated for the indicated measure. The number appearing in each flow-diagram element corresponds to the assessment criteria appearing in the *Case Eligibility Criteria* and *Numerator Criteria* tables.

Note: Newly adopted measures will be integrated into CP<sup>3</sup>R prior to their release in RQRS.

#### Measure Definitions

This document provides specifications for the following measures:

Measure	Measure Abbreviation	Measure Type
Salpingo-oophorectomy with omentectomy, debulking; cytoreductive surgery, or pelvic exenteration in Stages I-IIIC Ovarian cancer	OVSAL	Surveillance

These measures were developed in conjunction with the Society of Gynecologic Oncology.

Note: The ovarian chemotherapy measure OVCT has been removed from CP3R in the November 2015 release.

## Measure Type

There are several types of measures approved by the CoC. Evidence-based measures or **accountability** measures promote improvements in care delivery and are the highest standard for measurement. These measures demonstrate provider accountability, influence payment for services and promote transparency. The **quality improvement** measure function is to monitor the need for quality improvement or remediation. Generally, these measures are for individual program use. **Surveillance** measures are used to identify the status quo, generate information for decision making, and/or to monitor patterns and trends of care. The following Table summarizes the purposes and use of these measures:

<b>Measure Type</b>	<b>Measure definition and use</b>
<b>Accountability</b>	High level of evidence supports the measure, including multiple randomized control trials. These measures can be used for such purposes as public reporting, payment incentive programs, and the selection of providers by consumers, health plans, or purchasers.
<b>Quality Improvement</b>	Evidence from experimental studies, not randomized control trials supports the measure. These are intended for internal monitoring of performance within an organization.
<b>Surveillance</b>	Limited evidence exist that supports the measure or the measure is used for informative purposes to accredited programs. These measures can be used for to identify the status quo as well as monitor patterns and trends of care in order to guide decision-making and resource allocation.




---

**OVSAL – Ovarian Measure: Salpingo-oophorectomy with omentectomy, debulking/cytoreductive surgery, or pelvic exenteration in Stages I-IIIc Ovarian cancer**

---

**Measure Type:** Surveillance

Note: This measure applies to cases diagnosed in 2010 and later.

<b>Measure Item List</b>		
<b>FORDS Data Item</b>	<b>NAACCR #</b>	<b>Description</b>
Primary Site	400	Organ of origin of the cancer
Sex	220	Sex of patient
Age at Diagnosis	230	Age of patient at diagnosis
Sequence Number	560	Sequence of malignant and nonmalignant neoplasms over the lifetime
Histology	522	Microscopic or cellular anatomy of the cancer
Behavior Code	523	Neoplastic behavior of the cancer
Class of Case	610	Indicates the reporting facility's role in managing the cancer
CS Site-Specific Factor 2	2890	FIGO Stage
Clinical T	940	AJCC Clinical T
Clinical N	950	AJCC Clinical N
Clinical M	960	AJCC Clinical M
Pathologic T	880	AJCC Pathologic T
Pathologic N	890	AJCC Pathologic N
Pathologic M	900	AJCC Pathologic M
Surgical Procedure of the Primary Site at this facility	670	Surgical procedure of the primary site performed at this facility
Regional Lymph Nodes Examined	830	Total number of regional lymph nodes that were removed and examined
<i>Exclusion (This is a user field in CP<sup>3</sup>R, it is not a FORDS item)</i>	N/A	Field used to manually exclude cases

Case Eligibility Criteria			
Diagram Reference	Assessment	FORDS Item	FORDS Codes
1	Diagnosis of Ovarian cancer	Primary Site	C569
2	Exclude manually censored cases	<i>Exclusion</i> (This is a user field in CP <sup>3</sup> R, it is not a FORDS item)	Exclude: 80 - Patient enrolled in a clinical trial that directly impacts delivery of the standard of care
3	Female	Sex	2
4	Adult patient over the age of 17 at diagnosis	Age at Diagnosis	018-120
5	First or only tumor diagnosis	Sequence Number	00 or 01
6	Strictly epithelial histologies listed in AJCC 7 <sup>th</sup> ed.	Histology	Histology = 8000 - 8576
7	Invasive tumors	Behavior Code	3
8	All or part of the first course of treatment was performed at the reporting facility	Class of Case	10, 11, 12, 13, 14, 20, 21, or 22
9	Stages I-IIIIC (FIGO stage, substituted with clinical TNM where missing, followed by pathologic TNM AJCC 7 <sup>th</sup> ed.)	CS Site-Specific Factor 2 (FIGO)	Stage by <b>FIGO</b> (ssf2): Stage <b>I-IIIIC</b> : 100, 110, 120, 130, 200, 210, 220, 230, 300, 310, 320; or Stage <b>IIIIC</b> : 330 <b>OR</b>
		Clinical T	Stage by <b>Clinical TNM</b> : (if FIGO stage is missing or unknown): Stage <b>I-IIIIC</b> : Clinical T=(c1A,c1B,c1C,c2,c2A,c2B,c2C,c3,c3A,c3B), N=c0, M≠(c1,p1); or Stage <b>IIIIC</b> : Clinical T=c3C, N=c0, M≠(c1,p1); or any T, N=c1, M≠(c1,p1); <b>OR</b>
		Clinical N	Stage by <b>Pathologic TNM</b> : (if FIGO and clinical stage are missing or unknown): Stage <b>I-IIIIC</b> : Pathologic T=(p1A,p1B,p1C,p2,p2A,p2B,p2C,p3,p3A,p3B), N=(c0,p0), M≠(c1,p1); or Stage <b>IIIIC</b> : Pathologic T=p3C, N=(c0,p0), M≠(c1,p1); or any Pathologic T, N=p1, M≠(c1,p1); (blank Clinical/Pathologic M = c0)
		Clinical M	
		Pathologic T	
		Pathologic N	
		Pathologic M	
10	Any surgical excision or resection at this facility	Surgical Procedure of the Primary Site at this facility	25 - 90

Numerator Criteria			
Diagram Reference	Assessment	FORDS Item	FORDS Codes
11	Salpingo-oophorectomy with omentectomy, debulking/cytoreductive surgery, or pelvic exenteration. Additionally, for Stages I-III B, at least one regional lymph node was examined ( <i>this measure calculates the rate for this facility only*</i> )	Surgical Procedure of the Primary Site at this facility	<i>for Stages I-III B (by FIGO, clinical TNM, or pathologic TNM as defined above):</i> Surgery codes: 55-57, 60-63, 70-74 <i>and Regional Lymph Nodes Examined codes:</i> 01-90, 96, 97, 98  <b>OR</b>  <i>for Stage III C: (by FIGO, clinical TNM, or pathologic TNM as defined above):</i> Surgery codes: 55-57, 60-63, 70-74
		Regional Lymph Nodes Examined	

\*This is a surveillance measure, not to measure performance, but to calculate the percentage of Salpingo/debulking surgeries performed at this hospital. Salpingo/debulking surgery performed elsewhere is not included in the numerator in this measure.

Notes:

- 1) September 2015 CP3R release: Measure OVSAL was introduced.
- 2) November 2015 CP3R Updates:
  - a. Allow for manual exclusion with censor 80
  - b. Edit Histology regardless of FIGO.
- 3) August 2016 Update:
  - a. NAACCRv16, add c or p prefix to TNM.
- 4) June 2017 doc only correction CS Site-Specific Factor 2 #2890



**OVSAL – Ovarian Measure: Salpingo-oophorectomy with omentectomy, debulking/cytoreductive surgery, or pelvic exenteration in Stages I-IIIc Ovarian cancer**

